• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Natera Inc (NQ: NTRA )

    124.39 +0.95 (+0.77%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Natera Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
    From Natera, Inc.
    Via Business Wire
    The Latest Analyst Ratings for Natera
    Via Benzinga
    Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
    From Natera, Inc.
    Via Business Wire
    Analyst Expectations for Natera's Future
    Via Benzinga
    Analyst Ratings for Natera
    Via Benzinga
    Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
    From Natera, Inc.
    Via Business Wire
    Top 5 Health Care Stocks That May Collapse In November
    As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
    Via Benzinga
    Natera Announces Real-World Data Collaboration with Merck
    From Natera, Inc.
    Via Business Wire
    Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Natera Reports Third Quarter 2023 Financial Results
    From Natera, Inc.
    Via Business Wire
    Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
    From Natera, Inc.
    Via Business Wire
    Natera to Participate in November Investor Conferences
    From Natera, Inc.
    Via Business Wire
    NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
    From Natera, Inc.
    Via Business Wire
    Bull Of The Day: NeoGenomics
    NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
    Via Talk Markets
    Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
    From Natera, Inc.
    Via Business Wire
    Natera to Report its Third Quarter 2023 Results on November 8
    From Natera, Inc.
    Via Business Wire
    Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
    From Natera, Inc.
    Via Business Wire
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
    From Natera, Inc.
    Via Business Wire
    NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
    From Natera, Inc.
    Via Business Wire
    Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
    From Natera, Inc.
    Via Business Wire
    Natera Submits First PMA Module to the FDA for Signatera™
    From Natera, Inc.
    Via Business Wire
    Natera Announces Senior Leadership Appointments
    From Natera, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
    Via Benzinga
    Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
    From Natera, Inc.
    Via Business Wire
    Natera Announces Pricing of $250 Million Follow-On Offering
    From Natera, Inc.
    Via Business Wire
    Natera Launches Proposed Follow-On Offering
    From Natera, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.